Chemoprevention of Keratinocyte Carcinomas

Olivia M. Lucero; Fiona O.Reilly Zwald; David Lambert

doi:10.1007/978-3-030-50593-6_21

Chemoprevention of Keratinocyte Carcinomas

Olivia M. Lucero, Fiona O.Reilly Zwald, David Lambert

Dermatology

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

This chapter focuses on the use of retinoids in the chemoprevention of keratinocyte carcinomas (KC) and will aim to demystify their use in the clinical arena by offering a practical approach to optimize clinical benefits and minimize adverse effects. The last decade has ushered in a handful of agents with demonstrated efficacy in the prevention of KC including vismodegib, sirolimus, DNA repair enzymes, cyclooxygenase-2 (COX-2) inhibitors, and capecitabine which will be discussed. Topical imiquimod, 5-fluoruracil (5-FU), and photodynamic therapy have been detailed elsewhere (see Chaps. 2 and 4). Vismodegib is covered in detail in Chap. 22.

Original language	English (US)
Title of host publication	Skin Cancer Management
Subtitle of host publication	A Practical Approach
Publisher	Springer International Publishing
Pages	335-351
Number of pages	17
ISBN (Electronic)	9783030505936
ISBN (Print)	9783030505929
DOIs	https://doi.org/10.1007/978-3-030-50593-6_21
State	Published - Apr 26 2021

Keywords

Chemoprevention
DNA repair enzymes
Diclofenac
Mammalian target of rapamycin inhibitors (mTOR-1)
Nicotinamide
Systemic retinoids
Topical retinoid therapy

ASJC Scopus subject areas

General Medicine

Access to Document

10.1007/978-3-030-50593-6_21

Cite this

@inbook{7f536f848042473d90f7cd644d646ef3,

title = "Chemoprevention of Keratinocyte Carcinomas",

abstract = "This chapter focuses on the use of retinoids in the chemoprevention of keratinocyte carcinomas (KC) and will aim to demystify their use in the clinical arena by offering a practical approach to optimize clinical benefits and minimize adverse effects. The last decade has ushered in a handful of agents with demonstrated efficacy in the prevention of KC including vismodegib, sirolimus, DNA repair enzymes, cyclooxygenase-2 (COX-2) inhibitors, and capecitabine which will be discussed. Topical imiquimod, 5-fluoruracil (5-FU), and photodynamic therapy have been detailed elsewhere (see Chaps. 2 and 4). Vismodegib is covered in detail in Chap. 22.",

keywords = "Chemoprevention, DNA repair enzymes, Diclofenac, Mammalian target of rapamycin inhibitors (mTOR-1), Nicotinamide, Systemic retinoids, Topical retinoid therapy",

author = "Lucero, {Olivia M.} and Zwald, {Fiona O.Reilly} and David Lambert",

note = "Publisher Copyright: {\textcopyright} Springer Nature Switzerland AG 2021.",

year = "2021",

month = apr,

day = "26",

doi = "10.1007/978-3-030-50593-6_21",

language = "English (US)",

isbn = "9783030505929",

pages = "335--351",

booktitle = "Skin Cancer Management",

publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Chemoprevention of Keratinocyte Carcinomas

AU - Lucero, Olivia M.

AU - Zwald, Fiona O.Reilly

AU - Lambert, David

N1 - Publisher Copyright: © Springer Nature Switzerland AG 2021.

PY - 2021/4/26

Y1 - 2021/4/26

N2 - This chapter focuses on the use of retinoids in the chemoprevention of keratinocyte carcinomas (KC) and will aim to demystify their use in the clinical arena by offering a practical approach to optimize clinical benefits and minimize adverse effects. The last decade has ushered in a handful of agents with demonstrated efficacy in the prevention of KC including vismodegib, sirolimus, DNA repair enzymes, cyclooxygenase-2 (COX-2) inhibitors, and capecitabine which will be discussed. Topical imiquimod, 5-fluoruracil (5-FU), and photodynamic therapy have been detailed elsewhere (see Chaps. 2 and 4). Vismodegib is covered in detail in Chap. 22.

AB - This chapter focuses on the use of retinoids in the chemoprevention of keratinocyte carcinomas (KC) and will aim to demystify their use in the clinical arena by offering a practical approach to optimize clinical benefits and minimize adverse effects. The last decade has ushered in a handful of agents with demonstrated efficacy in the prevention of KC including vismodegib, sirolimus, DNA repair enzymes, cyclooxygenase-2 (COX-2) inhibitors, and capecitabine which will be discussed. Topical imiquimod, 5-fluoruracil (5-FU), and photodynamic therapy have been detailed elsewhere (see Chaps. 2 and 4). Vismodegib is covered in detail in Chap. 22.

KW - Chemoprevention

KW - DNA repair enzymes

KW - Diclofenac

KW - Mammalian target of rapamycin inhibitors (mTOR-1)

KW - Nicotinamide

KW - Systemic retinoids

KW - Topical retinoid therapy

UR - http://www.scopus.com/inward/record.url?scp=85148481078&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85148481078&partnerID=8YFLogxK

U2 - 10.1007/978-3-030-50593-6_21

DO - 10.1007/978-3-030-50593-6_21

M3 - Chapter

AN - SCOPUS:85148481078

SN - 9783030505929

SP - 335

EP - 351

BT - Skin Cancer Management

PB - Springer International Publishing

ER -

Chemoprevention of Keratinocyte Carcinomas

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this